Document is current
Any future updates will be listed below
-
Authors
Khan, Muhammad Ajmal https://orcid.org/0000-0002-3817-3631
Chang, Jinhee https://orcid.org/0000-0002-3603-403X
Song, Yang
Shetty, Amol C.
Nguyen, Triet
Waters, Danielle N.
Chowdhury, Dipanwita Dutta
Simms, Elan
Chan, Aaron
Tseng, Hwai Wei
Lam, Christine
Patel, Priyanshi
Tran, Lucas T.
Chen, Jiayu
Wang, Jarey H.
Nugent, Katriana
Ballew, Matthew
Lemtiri-Chlieh, Ghali
Carrieri, Francesca Anna
Malek, Reem
Wang, Hailun
Thielman, Noelle R. Jurcak https://orcid.org/0000-0002-2260-8055
Li, Keyu
Park, Ryan J. https://orcid.org/0000-0003-4725-2937
Hwang, William L.
Zheng, Lei https://orcid.org/0000-0003-4163-2541
Gabrielson, Kathleen
Tran, Phuoc T. https://orcid.org/0000-0002-0147-0376
Lafargue, Audrey https://orcid.org/0000-0001-9551-2815
- License Information
-
More Information
Article History
Received: 16 December 2024
Accepted: 8 April 2026
First Online: 22 May 2026
Competing interests
: P.T.T. has consulted and has received personal fees from NATSAR Pharmaceuticals, Johnson and Johnson, Regeneron, Bayer Healthcare, Novartis, Lantheus, Pfzier and RefleXion Medical Inc. P.T.T. also has a patent for 9114158 issued to Natsar Pharmaceuticals with royalties paid from Natsar Pharmaceuticals. L.Z. receives grant support from Bristol-Myers Squibb, Merck, Abbvie, Astrazeneca and Ipsen. L.Z. is a paid consultant/Advisory Board Member at Biosion, Pfizer, Amberstone, Fortress, Tallac and Fortvita. L.Z. is in the Speaker Bureau of Hengrui Pharma and Servier Pharmaceuticals. L.Z. holds shares at Amberstone, Alphamab, Cellaration and Mingruizhiyao. The other authors declare no competing interests.
